Fig. 2: Prevalence of HRD and HRD-related scores based on non-BRCA1/2 HRR gene variation origin, hit type, and HRD status. | npj Precision Oncology

Fig. 2: Prevalence of HRD and HRD-related scores based on non-BRCA1/2 HRR gene variation origin, hit type, and HRD status.

From: Homologous recombination deficiency among patients with germline or somatic non-BRCA1/2 homologous recombination repair gene variations

Fig. 2

a Patients with germline non-BRCA1/2 HRR variations demonstrated a significantly higher HRD+ rate than those with somatic variations. b Patients with germline P/LP non-BRCA1/2 HRR variations had a similar HRD+ rate to those with VUS, regardless of whether they were BAs or MAs. c Patients with class III variations had a significantly higher HRD+ rate than those with class II variations, regardless of whether they were BAs or MAs. GIS, TAI, LOH, and LST scores in HRD+ groups with germline (d) and somatic e variations, and in HRD- groups with germline (f) and somatic (g) variations. BAs biallelic alterations, GIS genomic instability score, HRD homologous recombination deficiency, LOH loss of heterozygosity, LP likely pathogenic, LST large-scale state transitions, MAs monoallelic alterations, P pathogenic, TAI telomeric allelic imbalance, VUS variants of uncertain significance. * p < 0.05; ** p < 0.01; ****p < 0.0001; ns not significant.

Back to article page